No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

Reproductive Solutions Reports ProteX Sperm Collection Solution Offers New Hope for Infertile Couples

Yields Better Specimen Quality for Fertility Clinic Use & Extends Sperm Viability to 48 Hours

Editor: What To Know

  • Keep sperm samples stable at the highest possible motility for up to 48 hours, allowing men to collect at home and deliver the sample to the clinic within the 48-hour window versus the 1-hour standard.
  • For men and their partners, ProteX also eliminates the pressure of producing a sample at a clinic and thereby helps improve the viability of the sample.
  • Unlike urine specimen cups traditionally used for semen collection, ProteX features an insulated design and an interior funnel that directs sperm to a small holding well that combine to prevent severe temperature fluctuations and minimize the surface area exposed to the environment.

Reproductive Solutions notes in a breakthrough for collecting sperm samples for fertility treatment, Reproductive Solutions (RSI) today announced the availability of a patented, FDA-listed semen collection container that improves specimen quality for in vitro fertilization and other assisted reproductive technologies.

Reproductive Solutions advises The ProteX™ container also preserves a high-quality sample for up to 48 hours compared to the 45 to 60 minutes of standard 50-year-old collection methods, enabling at-home collection while also easing bottlenecks at fertility clinic labs.

Unlike urine specimen cups traditionally used for semen collection, ProteX features an insulated design and an interior funnel that directs sperm to a small holding well that combine to prevent severe temperature fluctuations and minimize the surface area exposed to the environment. These and other features reduce damage to semen quality, resulting in increased motility, sperm count and fertilization capability.

Developed by reproductive health specialists at Texas Tech University and studied extensively before market introduction, the ProteX solution has been proven to:

  • Protect sperm from thermal shock, pH imbalance and osmotic stress that cause cellular damage to sperm at the time of collection

  • Slow sperm cooling rate to just 0.5° F per minute compared to a loss of 30° F measured in standard specimen cups in the first 10 minutes alone

  • Provide up to 50% higher sperm motility than the generic specimen cup, in which sperm samples have a declining motility rate from the moment of collection

  • Increase the likelihood of egg fertilization by keeping sperm acrosomes up to 45% more intact than a standard specimen cup at 24 hours, with an even higher percentage of intact acrosomes at 1, 3, 6, 12 and 18 hours

  • Keep sperm samples stable at the highest possible motility for up to 48 hours, allowing men to collect at home and deliver the sample to the clinic within the 48-hour window versus the 1-hour standard

For men and their partners, ProteX also eliminates the pressure of producing a sample at a clinic and thereby helps improve the viability of the sample. Studies show the stress hormone cortisol, which is released in the body as a chemical expression of psychosocial stress, negatively impacts progressive motility and sperm count.

For fertility clinics, ProteX eliminates the need for collection rooms, increases the number of patients who can be treated, and simplifies lab scheduling by extending sample viability to up to 48 hours rather than requiring processing within 45-60 minutes.

“Roughly 40% of infertility problems can be traced to the male partner, yet there has been little focus on improving the male side of the fertility equation in the clinical work,” said Diana Peninger, President and CEO of Reproductive Solutions. “As the first advance in semen collection, our ProteX container not only allows samples to be collected at home without compromising quality but also provides a healthier specimen with the potential to increase the odds of conception. This is a significant development for couples as well as clinics.”

The ProteX solution is currently in use at several fertility clinics and will be available directly to consumers this spring.

 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy